Myovant Sciences Ltd. (MYOV)
| Market Cap | 1.26B |
| Revenue (ttm) | 144.95M |
| Net Income (ttm) | -238.46M |
| Shares Out | 93.31M |
| EPS (ttm) | -2.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,081,445 |
| Open | 13.75 |
| Previous Close | 13.89 |
| Day's Range | 13.18 - 14.00 |
| 52-Week Range | 13.14 - 27.43 |
| Beta | 2.72 |
| Analysts | Buy |
| Price Target | 28.00 (+107.4%) |
| Earnings Date | Jan 26, 2022 |
About MYOV
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for MYOV stock is "Buy." The 12-month stock price forecast is 28.00, which is an increase of 107.41% from the latest price.
News
Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, ...
BASEL, Switzerland, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and con...
Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021
BASEL, Switzerland, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced preliminary financial results ...
Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
BASEL, Switzerland, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Execut...
Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Impr...
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, Inc. announced publication of patient-perception data for its FDA-approved OAB therapy, GEMTESA® (vibegron), compared to placebo.
Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of ...
LONDON and NEW YORK, Dec. 10, 2021 /PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly-owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovant) and...
Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference
BASEL, Switzerland, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th Annua...
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Resul...
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Publication of Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
Nancy Valente, M.D. Joins Myovant Sciences' Board of Directors
BASEL, Switzerland and LONDON, United Kingdom, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the...
All You Need to Know About Myovant Sciences (MYOV) Rating Upgrade to Buy
Myovant Sciences (MYOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Spirovant to Present SP-101 Data at the 2021 North American Cystic Fibrosis Conference
PHILADELPHIA, Oct. 28, 2021 /PRNewswire/ -- Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today announced ...
Why Did Myovant Sciences Shares Fall Despite Q2 Earnings Beat?
Tucked in its Q2 earnings release, Myovant Sciences Ltd (NYSE: MYOV) said that Pfizer Inc (NYSE: PFE) has notified its option decision for international rights to relugolix in oncology. Pfizer declined ...
Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 32.35% and 7.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates
BASEL, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced financial results for the seco...
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endome...
BASEL, Switzerland and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its onc...
Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion
Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26,...
BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and con...
Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissu...
RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia
Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactiv...
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Presents Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Showing No Significant Effects on Blood Pressure or Heart Rate
Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA
Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Manag...
BASEL, Switzerland and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted fo...
Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for O...
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present New Data at the Virtual 2021 Annual Meeting of the American Urological Association
Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference
BASEL, Switzerland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global Hea...
Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer
BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra as ...
Here's Why Myovant Sciences Stock Is Falling Today
Second-quarter earnings results were a little bit disappointing.
Myovant Sciences (MYOV) Reports Q1 Loss, Misses Revenue Estimates
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -219.05% and -32.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?